{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:07:28Z","timestamp":1789042048013,"version":"build-2803163510"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Urinary bladder cancer (UBC) remains a major global health burden, with high recurrence rates and limited therapeutic options for patients who fail standard intravesical and systemic treatments. In recent years, Living Cancer Therapeutics (LCTs)\u2014including bacteria-, virus-, and microbiome-based oncobiotics\u2014emerged as innovative biological strategies capable of overcoming key limitations of conventional cancer therapies. This article is a narrative review aimed at mapping the mechanistic landscape, historical development, and translational progress of LCTs in UBC. Five interrelated mechanisms were identified through which oncobiotics exert therapeutic effects: (i) direct tumor destruction via bacterial colonization, cytolysis, and metabolic deprivation; (ii) immune system modulation through innate and adaptive immune activation; (iii) engineered drug delivery and synthetic biology enabling programmable, tumor-restricted payload release; (iv) oncolytic virotherapy combining selective tumor lysis with immune priming; and (v) microbiome-driven immune modulation influencing treatment responsiveness. Although conceptually distinct, these mechanisms frequently overlap in practice, reflecting the multifunctional nature of living therapeutics. Clinical translation has progressed furthest for immune-mediated approaches such as Bacillus Calmette\u2013Gu\u00e9rin (BCG) and selected oncolytic viral platforms, particularly in BCG-unresponsive UBC, although current evidence remains limited by small studies, heterogeneous endpoints, and insufficient long-term follow-up. Advances in genetic engineering and synthetic biology have enabled the development of increasingly sophisticated investigational platforms, including engineered oncolytic viruses, programmable bacterial vectors, and microbiome-based therapeutic strategies; however, most remain at an early preclinical or translational stage. UBC may represent a favorable setting for LCT development due to the accessibility of the bladder and the established use of intravesical therapies, although delivery efficiency and therapeutic durability remain important challenges. Despite encouraging early findings, significant limitations persist, including biological delivery barriers, host immune neutralization, interpatient heterogeneity, biosafety concerns, regulatory complexity, and the scarcity of late-phase randomized clinical data. Further translational research, biomarker development, and long-term clinical evaluation will therefore be required to determine the future role of LCTs in UBC management.<\/jats:p>","DOI":"10.3389\/fonc.2026.1845015","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:32:38Z","timestamp":1782102758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics"],"prefix":"10.3389","volume":"16","author":[{"given":"Suleiman","family":"Abuhasanein","sequence":"first","affiliation":[{"name":"Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg","place":["Gothenburg, Sweden"]},{"name":"Department of Surgery, Urology section, N\u00c4L and Uddevalla (NU)-Hospital Group","place":["Uddevalla, Region V\u00e4stra G\u00f6taland, Sweden"]},{"name":"Department of Research and Development, NU-Hospital Group","place":["Trollh\u00e4ttan, Region V\u00e4stra G\u00f6taland, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00345-024-04949-8","article-title":"Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates","volume":"42","author":"W\u00e9ber","year":"2024","journal-title":"World J Urol"},{"key":"B2","volume-title":"Report on Bladder Cancer","author":"Carroll","year":"2016"},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs","volume":"27","author":"Sievert","year":"2009","journal-title":"World J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-004128","article-title":"Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease study 2019","volume":"6","author":"Saeid","year":"2021","journal-title":"BMJ Global Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.cd-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioactmat.2025.09.012","article-title":"Engineered bacteria and bacteria-derived nanomaterials for cancer therapy: mechanisms, designs and advances","volume":"55","author":"Cheng","year":"2026","journal-title":"Bioact Mater"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1603671","article-title":"Unlocking the potential of engineered microbes in immunotoxin-based cancer therapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front Microbiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","article-title":"Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments","volume":"24","author":"Yan","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.10.101","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114443","article-title":"Decorated bacteria and the application in drug delivery","volume":"188","author":"Wu","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119726","article-title":"Bacterial therapy of cancer: a way to the dustbin of history or to the medicine of the future","volume":"24","author":"Ikryannikova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/mou.0000000000001331","article-title":"Oncolytic virus therapy for nonmuscle-invasive bladder cancer: current status and future directions","author":"Kitamura","year":"2025","journal-title":"Curr Opin Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1469-0691.2012.03945.x","article-title":"Louis Pasteur, from crystals of life to vaccination","volume":"18","author":"Berche","year":"2012","journal-title":"Clin Microbiol Infection"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3010285","article-title":"Enteric bacteria and cancer stem cells","volume":"3","author":"Sun","year":"2011","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","article-title":"The influence of complicating diseases upon leukaemia","volume":"127","author":"Dock","year":"1904","journal-title":"Am J Med Sci (1827-1924)"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.3c07727","article-title":"Revisiting Coley\u2019s toxins: immunogenic cardiolipins from Streptococcus pyogenes","volume":"145","author":"Shin","year":"2023","journal-title":"J Am Chem Soc"},{"key":"B19","article-title":"Disappearance of a recurrent carcinoma after injections of mixed toxins","volume":"55","author":"Coley","year":"1912","journal-title":"Ann Surg"},{"key":"B20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1017\/S002217240003309X","article-title":"The Micrococcus neoformans: its cultural characters and pathogenicity and the results of the estimation of the opsonic and agglutinative properties of the serum of patients suffering from Malignant disease on this organism and on the Staphylococcus albus","volume":"7","author":"Dudgeon","year":"1907","journal-title":"J Hyg (Lond)"},{"key":"B21","first-page":"47","article-title":"Cancer and infection","volume":"20","author":"Burke","year":"2008","journal-title":"Aust J Med Herbalism"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3171\/2023.6.jns23243","article-title":"Oncolytic viral therapy: a review and promising future directions","volume":"140","author":"Reddy","year":"2024","journal-title":"J Neurosurg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-1231","article-title":"FDA approval summary: Nogapendekin alfa inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ","volume":"31","author":"Heiss","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189112","article-title":"Bacteria-based cancer therapy: looking forward","volume":"1879","author":"Tieu","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B27","doi-asserted-by":"crossref","first-page":"12980","DOI":"10.3390\/ijms222312980","article-title":"Fighting cancer with bacteria and their toxins","volume":"22","author":"Trivanovic","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008004","article-title":"Fas-associated factor 1 mediates NADPH oxidase-induced reactive oxygen species production and proinflammatory responses in macrophages against Listeria infection","volume":"15","author":"Kim","year":"2019","journal-title":"PloS Pathog"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105086","article-title":"Bacteria\u2010elicited specific thrombosis utilizing acid\u2010induced cytolysin A expression to enable potent tumor therapy","volume":"9","author":"Qin","year":"2022","journal-title":"Adv Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/cgt.2012.86","article-title":"Bifidobacterium infantis-mediated HSV-TK\/GCV suicide gene therapy induces both extrinsic and intrinsic apoptosis in a rat model of bladder cancer","volume":"20","author":"Yin","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"B31","doi-asserted-by":"crossref","first-page":"2397808","DOI":"10.1155\/2018\/2397808","article-title":"Microorganisms in the treatment of cancer: advantages and limitations","volume":"2018","author":"Lukasiewicz","year":"2018","journal-title":"J Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42269-019-0227-2","article-title":"Toll-like receptors activation, signaling, and targeting: an overview","volume":"43","author":"El-Zayat","year":"2019","journal-title":"Bull Natl Res Cent"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01049","article-title":"Modulation of the innate immune response by targeting toll-like receptors: a perspective on their agonists and antagonists","volume":"63","author":"Federico","year":"2020","journal-title":"J Med Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41598-018-36926-8","article-title":"The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant","volume":"9","author":"Laut\u00e9-Caly","year":"2019","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.mib.2015.12.001","article-title":"Bacterial chemotaxis: information processing, thermodynamics, and behavior","volume":"30","author":"Micali","year":"2016","journal-title":"Curr Opin Microbiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41586-025-09249-8","article-title":"Microbiota-driven antitumour immunity mediated by dendritic cell migration","volume":"644","author":"Lin","year":"2025","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01426.x","article-title":"Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors","volume":"101","author":"Seow","year":"2010","journal-title":"Cancer Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/evidoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.03.139","article-title":"Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen","volume":"186","author":"Ahmad","year":"2011","journal-title":"J Urol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.3568","article-title":"Administration of Mycobacterium phlei cell wall-nucleic acid complex in the immediate postoperative period for the treatment of non-muscle-invasive bladder cancer","volume":"10","author":"Morales","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1189","article-title":"Intravesical Bacillus Calmette Guerin combined with a cancer vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients","volume":"23","author":"Derre","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-019-0112-z","article-title":"Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma","volume":"27","author":"Portal","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.09.031","article-title":"Bacillus Calmette-Guerin (BCG): its fight against pathogens and cancer","volume":"39","author":"Sfakianos","year":"2021","journal-title":"Urol Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.11.124","article-title":"Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer","volume":"181","author":"Bisiaux","year":"2009","journal-title":"J Urol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/jci148291","article-title":"BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases","volume":"131","author":"Singh","year":"2021","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2012.04614.x","article-title":"Is interferon-gamma the right marker for bacille Calmette-Gu\u00e9rin-induced immune protection? The missing link in our understanding of tuberculosis immunology","volume":"169","author":"Abebe","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1061186X.2025.2512619","article-title":"Engineered Salmonella carrying siRNA-PD-1 shrinks orthotopically implanted bladder cancer in rats","author":"Shi","year":"2025","journal-title":"Journal of Drug Targeting"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03274-6","article-title":"Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma","volume":"72","author":"Sonpavde","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2023.102380","article-title":"Design of synthetic bacterial biosensors","volume":"76","author":"Chiang","year":"2023","journal-title":"Curr Opin Microbiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cphc.201900739","article-title":"Synthetic biology enables programmable cell\u2010based biosensors","volume":"21","author":"Hicks","year":"2020","journal-title":"ChemPhysChem"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122951","article-title":"Engineered VNP20009 expressing IL-15&15R\u03b1 augments anti-tumor immunity for bladder cancer treatment","volume":"315","author":"Liu","year":"2025","journal-title":"Biomaterials"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17071125","article-title":"Immunogenic human papillomavirus pseudovirus-mediated suicide-gene therapy for bladder cancer","volume":"17","author":"Hojeij","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.04.015","article-title":"Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus","volume":"29","author":"Wan","year":"2021","journal-title":"Mol Ther"},{"key":"B57","article-title":"Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel","volume":"62","author":"Zhang","year":"2002","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1089\/hum.2018.026","article-title":"The oncolytic adenovirus XVir-N-31 as a novel therapy in muscle-invasive bladder cancer","volume":"30","author":"Lichtenegger","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-4022","article-title":"Phase I trial of an ICAM-1-targeted immunotherapeutic-Coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-08-0238","article-title":"Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer","volume":"68","author":"Hadaschik","year":"2008","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607296","article-title":"Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models","volume":"9","author":"Potts","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100409","article-title":"Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide","volume":"82","author":"Myers","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.422","article-title":"Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma","volume":"9","author":"Miest","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B68","unstructured":"OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer\n          \n          ClinicalTrials.gov\n          \n          2024"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25614","article-title":"Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus","volume":"9","author":"Oseledchyk","year":"2018","journal-title":"Oncotarget"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201016","article-title":"Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models","volume":"33","author":"Daniel","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2018.02.001","article-title":"Oncolytic immunotherapy for bladder cancer using Coxsackie A21 virus","volume":"9","author":"Annels","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"B72","doi-asserted-by":"crossref","first-page":"12157","DOI":"10.1038\/s41598-018-29054-w","article-title":"The urinary microbiome associated with bladder cancer","volume":"8","author":"Bucevic Popovic","year":"2018","journal-title":"Sci Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092068","article-title":"The urinary microbiome: Role in bladder cancer and treatment","volume":"12","author":"Friedrich","year":"2022","journal-title":"Diagnostics"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00643-7","article-title":"The urinary microbiome and anticancer immunotherapy: The potentially hidden role of unculturable microbes","volume":"14","author":"Bersanelli","year":"2019","journal-title":"Target Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.09.031","article-title":"Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer","volume":"179","author":"Naito","year":"2008","journal-title":"J Urol"},{"key":"B76","doi-asserted-by":"crossref","DOI":"10.1007\/s00284-019-01679-8","article-title":"Probiotic bacteria: A promising tool in cancer prevention and therapy","volume":"76","author":"Gorska","year":"2019","journal-title":"Curr Microbiol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.11.004","article-title":"Tweak to treat: Reprograming bacteria for cancer treatment","volume":"7","author":"Sieow","year":"2021","journal-title":"Trends Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c11601","article-title":"An engineered bacteria-hybrid microrobot with the magnetothermal bioswitch for remotely collective perception and imaging-guided cancer treatment","volume":"16","author":"Chen","year":"2022","journal-title":"ACS Nano"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101389","article-title":"Targeting tumor hypoxia with nanoparticle-based therapies: Challenges, opportunities, and clinical implications","volume":"17","author":"Debnath","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-155","article-title":"A novel Bifidobacterium infantis-mediated TK\/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer","volume":"28","author":"Tang","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"13443","DOI":"10.1038\/s41598-025-96419-3","article-title":"Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer","volume":"15","author":"Pannhausen","year":"2025","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2024.100037","article-title":"Current status and research progress of oncolytic virus","volume":"2","author":"Chen","year":"2024","journal-title":"Pharm Sci Adv"}],"updated-by":[{"DOI":"10.3389\/fonc.2026.1951323","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1845015\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:08:35Z","timestamp":1789038515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1845015\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":82,"alternative-id":["10.3389\/fonc.2026.1845015"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1845015","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1845015"}}